


67
 15. (amended) The compound of claim 14 wherein R² is -CH₂-(CH₂)_iN(R³)₂,
 -NR⁵-(CH₂)_iN(R³)₂, -S-(CH₂)_iN(R³)₂, -O-(CH₂)_iN(R³)₂, [-O-(CH₂)_iNR⁵C(NR⁵)(NR³)₂,] -O-
(CH₂)_iNR⁵C(NR⁵)N(R³)₂, -(CH₂)₁₋₂-O-(CH₂)_iN(R³)₂, -R⁶-CH₂-CHR³¹-N(R³)₂, -R⁶-(R⁷)_v-N(R³)₂,
 [-R⁶-(CH₂)_i-NR⁵C(NR⁵)(NR³)₂,] -R⁶-(CH₂)_i-NR⁵C(NR⁵)N(R³)₂, or [-CH₂-(CH₂)_iNR⁵C(NR⁵)(NR³)₂,]
-CH₂-(CH₂)_iNR⁵C(NR⁵)N(R³)₂.

REMARKS

Claims 1-30 are pending in this reissue application. By way of this amendment, a portion of the specification and claims 3, 4, 14, and 15, have been amended. No claims have been added or canceled. U.S. Patent No. 6,028,183 (the 183 patent), which was filed on November 7, 1997 as U.S. application serial no. 08/966,392 (the 392 application), issued on February 22, 2000. This paper is being filed within two years of the issue date.


Applicants hereby seek reissue of the 183 patent because compound claims 3, 4, 14, and 15 erroneously contain substituent moieties that are technically incorrect. The amendments made herein are being made to correct this error.

In this regard, claim 3, which depends on claim 1, is directed to a compound of the formula:



wherein R² is defined as, among other things, the group -R⁶-(CH₂)_tNR⁵C(NR⁵)(NR³)₂ (see, the 183 patent at column 79, lines 1-2). The substituent group, as written, however, contains an insufficient number of chemical bonds to the nitrogen atoms due to the inadvertent misplacement of the parenthesis associated with the group (NR³)₂. The recited structure is technically incorrect, as several of the nitrogen atoms are divalent.

Applicants have addressed this typographical error by amending claim 3 to recite the terminal portion of the R² substituent as N(R³)₂. This amendment assures that the substituent contains the intended terminal guanidine functionality. The technically correct R² substituent may be represented structurally as:



Claims 4, 14, 15 also contain the inadvertent misplacement of the parenthesis associated with $\text{NR}^5\text{C}(\text{NR}^5)\text{N}(\text{R}^3)_2$. For example, claim 4 recites, among other things, the groups $-\text{O}-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)(\text{NR}^3)_2$, $-\text{R}^6-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)(\text{NR}^3)_2$, and $-\text{CH}_2-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)(\text{NR}^3)_2$. Accordingly, Applicants have amended claim 4 to replace these structures with $-\text{O}-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)\text{N}(\text{R}^3)_2$, $-\text{R}^6-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)\text{N}(\text{R}^3)_2$, and $-\text{CH}_2-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)\text{N}(\text{R}^3)_2$, respectively. Claim 14 recites the group $-\text{R}^6-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)(\text{NR}^3)_2$. Applicants have amended claim 14 to replace this structure with $-\text{R}^6-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)\text{N}(\text{R}^3)_2$. Claim 15 recites, among other things, the groups $-\text{O}-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)(\text{NR}^3)_2$, $-\text{R}^6-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)(\text{NR}^3)_2$, and $-\text{CH}_2-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)(\text{NR}^3)_2$. Applicants have amended claim 15 to replace these structures with $-\text{O}-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)\text{N}(\text{R}^3)_2$, $-\text{R}^6-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)\text{N}(\text{R}^3)_2$, and $-\text{CH}_2-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)\text{N}(\text{R}^3)_2$, respectively. The specification has also been amended, where appropriate, to correct the inadvertent placement of the parentheses in the guanidine functionality and to reflect the changes made to the foregoing claims.

Based on a straightforward chemical interpretation of $-\text{R}^6-(\text{CH}_2)_t\text{NR}^5\text{C}(\text{NR}^5)(\text{NR}^3)_2$, it is clear that the misplacement of the parenthesis is simply a typographical error. Thus, support for the requested amendments is implicit in the claims. Nevertheless, support for the amendments is also provided in the specification. For example, at column 45, lines 1-10, Applicants specifically describe guanidine functionalities as preferred R^2 groups. Accordingly, the requested changes do not introduce new matter and are fully supported by the application, as originally filed.

THE **WORLD'S** **LARGEST** **BOOKSTORE**

Claims 4, 5, 14, and 15, as amended herein, are fully commensurate with the disclosure of the 183 patent as well as the underlying 392 application. The error being corrected in this reissue application up to the time of filing of this declaration under 37 C.F.R. §1.175(a) arose without any deceptive intention on the part of the applicants and/or patentees.

In view of the foregoing, Applicants respectfully request approval of the changes to claim 3, 4, 14, and 15.

Respectfully submitted,

(m.f.d.)—

Gregory L. Hillyer
Registration No. 44,154

Date: February 21, 2002

WOODCOCK WASHBURN LLP
One Liberty Place - 46th Floor
Philadelphia, PA 19103
(215) 568-3100